Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Postgraduate medicine

• Publication date

  2016-10-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00325481.2016.1241663PMID 27690710
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Patient-Centered Outcomes Research Institute

  2017cited by this paper
• Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial.

  2016cited by this paper
• Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

  2015cited by this paper
• Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

  2015cited by this paper
• Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial.

  2015cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

  2015cited by this paper
• Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

  2015influential reference
• One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

  2015cited by this paper
• New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

  2015cited by this paper
• Women With Gestational Diabetes Mellitus Randomized to a Higher–Complex Carbohydrate/Low-Fat Diet Manifest Lower Adipose Tissue Insulin Resistance, Inflammation, Glucose, and Free Fatty Acids: A Pilot Study

  2015cited by this paper
• An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

  2015cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cited by this paper
• Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

  2014cited by this paper
• The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010

  2013cited by this paper
• Barriers to Insulin Progression Among Patients With Type 2 Diabetes

  2013cited by this paper
• The Center For Medicare And Medicaid Innovation's blueprint for rapid-cycle evaluation of new care and payment models.

  2013cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013influential reference
• Are current clinical trials in diabetes addressing important issues in diabetes care?

  2013cited by this paper
• Diabetes Treatment Satisfaction Questionnaire: (DTSQ)

  2013cited by this paper
• Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems: The Adherence and Intensification of Medications Cluster Randomized, Controlled Pragmatic Trial

  2012cited by this paper
• Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.

  2011cited by this paper
• A pragmatic view on pragmatic trials

  2011cited by this paper
• Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the National Heart, Lung, and Blood Institute workshop.

  2011influential reference
• Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe

  2010cited by this paper
• A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers

  2009cited by this paper
• Patient-important outcomes in registered diabetes trials.

  2008cited by this paper
• Primary care physician beliefs about insulin initiation in patients with type 2 diabetes

  2008cited by this paper
• The triple aim: care, health, and cost.

  2008cited by this paper
• Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.

  2006cited by this paper
• Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.

  2005cited by this paper
• External validity of randomised controlled trials: "to whom do the results of this trial apply?".

  2005cited by this paper
• National Committee for Quality Assurance.

  2004cited by this paper
• Standards of medical care in diabetes.

  2004cited by this paper
• Randomized, controlled trials, observational studies, and the hierarchy of research designs.

  2000cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

  1995cited by this paper
• A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).

  1995cited by this paper
• Explanatory and pragmatic attitudes in therapeutical trials.

  1967cited by this paper

• Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization

  2025cites this paper
• Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study

  2021cites this paper
• Studies for labeling versus reimbursement

  2021cites this paper
• Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control.

  2020cites this paper
• (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

  2020cites this paper
• Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial

  2020cites this paper
• A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study

  2020cites this paper
• Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

  2019cites this paper
• Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

  2019cites this paper
• Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study

  2019cites this paper
• Pragmatic Trials and New Informatics Methods to Supplement or Replace Phase IV Trials

  2019cites this paper
• Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice

  2018cites this paper
• Levator Pull-Out Suture Technique for Immediate Postoperative Correction of Eyelid Asymmetry After Ptosis Surgery in Asians

  2018cites this paper
• Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

  2017cites this paper
• Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures

  2017cites this paper